Results 21 to 30 of about 79,483 (168)

Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.

open access: yesPLoS ONE, 2010
BackgroundThe majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral treatment using a fixed dose first-line antiretroviral regimen containing stavudine, lamivudine, and nevirapine. One of the primary concerns
Kathryn M Chu   +5 more
doaj   +1 more source

Toosendanin Induces Hepatocyte Damage by Inhibiting Autophagic Flux via TFEB-Mediated Lysosomal Dysfunction

open access: yesPharmaceuticals, 2022
Toosendanin (TSN) is a triterpenoid from the fruit or bark of Melia toosendan Sieb et Zucc, which has clear antitumor and insecticidal activities, but it possesses limiting hepatotoxicity in clinical application.
Li Luo   +7 more
doaj   +1 more source

Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

open access: yesBMC Cancer, 2018
Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients receiving erlotinib treatment prompting delay or termination of treatment. Only
Min Kyoung Kim   +5 more
doaj   +1 more source

Prevalence of ABCC3‐1767G/A polymorphism among patients with antiretroviral‐associated hepatotoxicity

open access: yesMolecular Genetics & Genomic Medicine, 2020
Background Plasma concentrations of antiretrovirals (ARVs) regimens have considerably varied in individuals of human immunodeficiency virus (HIV) because of variations in the expression of drug‐metabolizing and transporter genes.
HariOm Singh   +3 more
doaj   +1 more source

Evaluate the value of prolonging the duration of tiopronin for injection administration in preventing hepatotoxicity

open access: yesScientific Reports
As part of supportive therapy, prophylaxis with tiopronin for injection (TI) against common hepatotoxicity complications has often been used. However, methods to prevent hepatotoxicity have not been established. Therefore, our study was aimed to find out
Hongye Yang   +6 more
doaj   +1 more source

Acetaminophen Hepatotoxicity [PDF]

open access: yesSeminars in Liver Disease, 2019
AbstractAcetaminophen (APAP) is one of the most popular and safe pain medications worldwide. However, due to its wide availability, it is frequently implicated in intentional or unintentional overdoses where it can cause severe liver injury and even acute liver failure (ALF).
Anup, Ramachandran, Hartmut, Jaeschke
openaire   +2 more sources

Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: A nationwide hospitalization analysis

open access: yesLiver Research, 2021
Background and aims: Anti-neoplastic immunotherapy has revolutionized cancer management; however, its safety profile with respect to liver-related injury remains largely unexplored.
Simcha Weissman   +6 more
doaj   +1 more source

Papaverine and hepatotoxicity [PDF]

open access: yesPostgraduate Medical Journal, 1980
Abstract Six of 14 patients receiving a sustained release papaverine preparation developed abnormal liver function tests. One patient had jaundice and another abnormal liver histology on a biopsy specimen. This is only the third report of impaired liver function following the administration of papaverine--a drug which has been used in ...
M S, Pathy, A J, Reynolds
openaire   +2 more sources

Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis.

open access: yesPLoS ONE, 2019
OBJECTIVE:This study aimed to evaluate the risk for hepatotoxicity with nimesulide, a non-steroidal anti-inflammatory drug (NSAID) available in Republic of Korea but withdrawn from the market in several countries.
Jeongyoon Kwon   +3 more
doaj   +1 more source

Greater Celandine hepatotoxicity: a clinical review

open access: yesAnnals of Hepatology, 2012
Herbal hepatotoxicity is a rare and poorly described disease because reported cases are mostly scattered and lack an appropriate causality assessment.
Rolf Teschke, M.D.   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy